Hypercholesterolemia

3 articles published between July 18, 2026 and September 3, 2026.

Covered in Body and Policy.

WHAT THE STUDY ACTUALLY SAYS

Inclisiran beat bempedoic acid on LDL cholesterol in a head-to-head

In the Novartis-funded VICTORION-Challenge trial, twice-yearly inclisiran cut LDL 56.3% at day 150 against 15.4% for daily bempedoic acid — an open-label comparison of a surrogate marker, not outcomes.

3 min read

WHAT THE STUDY ACTUALLY SAYS

An oral PCSK9 pill cut LDL 65% and beat every other oral nonstatin drug

In the phase 3 CORALreef AddOn head-to-head, enlicitide dropped LDL cholesterol 64.6% at day 56 — far past ezetimibe, bempedoic acid, or the two combined.

4 min read

THE DRUG DOCKET

FDA approves the first pill in a cholesterol drug class that has only ever been injectable

Lipfendra cut LDL cholesterol by more than half in two trials. Its significance is less the number than the format: a once-daily tablet where every prior PCSK9 inhibitor required a needle.

4 min read

This page indexes this newspaper’s reporting on Hypercholesterolemia. It is not a medical reference entry, and nothing here is medical advice. See our editorial standards.

Hypercholesterolemia

Inclisiran beat bempedoic acid on LDL cholesterol in a head-to-head

An oral PCSK9 pill cut LDL 65% and beat every other oral nonstatin drug

FDA approves the first pill in a cholesterol drug class that has only ever been injectable

Reported alongside